LexBlog IP

OCTOBER 27, 2021

Patent and Trademark Office Patent Trial and Appeal Board (PTAB) recently released an updated Orange Book patent/biologic patent study on August 11, 2021. The first study covering these topics was released on March 13, 2018, and the second on July 18, 2019. Trends Over Time.

Patent 52

Patent Settlement Litigation Reporting 52

LexBlog IP

JUNE 30, 2023

As we previously reported , the FDA first approved CYLTEZO in 2017, and in 2021 approved its supplemental Biologics License Application as the first and, at present, still only, HUMIRA® (adalimumab) biosimilar to receive interchangeable status. Stay tuned to Big Molecule Watch for continued updates on this topic.

Designs 52

Designs Design Branding Brands 52

LexBlog IP

JULY 16, 2023

One directed to the frequency of so-called serial/parallel petition filings , and the other pertaining to Orange Book/Biologics patents. Second, the biologic aspect of the Study shows biologics constitute roughly 3-4% of petition filings over the past three years.

Patent 52

Patent Litigation Intellectual Property 52

The IPKat

MAY 12, 2023

The AmeriKat is particularly looking forward to the session on "Managing the Implications of the EPO's Decisions in BOA Referral G 2/21" and, as ever, her favorite favorite topic - SPCs. She will be reporting from the event, so look out for posts for those who are unable to attend.

Litigation 57

Litigation Patent Reporting 57

LexBlog IP

SEPTEMBER 24, 2022

With respect to fostering a biological data ecosystem, the Executive Order sets forth a Data for the Bioeconomy Initiative (Data Initiative) to “ensure that high-quality, wide-ranging, easily accessible, and secure biological data sets can drive breakthroughs for the United States bioeconomy.” ” Data Initiative.

Privacy 52

Privacy Technology Government Intellectual Property 52

LexBlog IP

AUGUST 24, 2023

In continuation of Goodwin’s previous webinar series concerning biosimilars, Big Molecule Watch is launching the 2023-2024 webinar series , which will dive deep into some of the key topics pertaining to this burgeoning industry and corresponding area of law.

Marketing 52

Marketing Marketing Registration Litigation 52

SpicyIP

NOVEMBER 8, 2023

Unlike small molecule drugs, biologics are large and complex substances. Typically, biologics are produced from living cells with the exception of emerging technologies such as the mRNA platform. The discovery, development and patenting of biologics has been historically tied to the ‘product of nature’ question under patent law.

Invention 69

Invention Patent Art Patent Law 69

The IPKat

MARCH 28, 2022

The conference lasted almost three days and with a large number of topics having been discussed. The IPKat reports on some of the trends and topics from the conference below. In fact, manufacturing is key in the biosimilars/biologics/antibodies area, even more than it was in the field of small molecules.

Reporting 76

Reporting Litigation Patent Confidentiality 76

LexBlog IP

APRIL 29, 2022

The BsUFA is a law authorizing FDA to assess and collect fees from drug manufacturers that submit Biological License Applications for biosimilar products. The testimony spanned many topics, but notably the FDA discussed the progress of biosimilar approvals, including its impact on cost. decrease in price (for insulin glargine) to a 42.2%

Licensing 52

Licensing Law Intellectual Property 52

IPilogue

AUGUST 5, 2021

Although the Canadian legalization of psilocybin, similar to cannabis, is an interesting and contentious topic, this article intends to highlight the potential patentability of psilocybin and its derivatives, as well as the current trends in the field. In 2020, the sales of cannabis products hit $2.6 Current Trends in Psychedelic Patenting.

Patent 59

Patent Invention Journalism Ownership 59

The IPKat

MARCH 21, 2024

The patent related to the problem of how to test biological samples for the presence of many different biological molecules at once, instead of having to run many separate tests for the presence of each type of molecule. How much the description should be used to interpret the claims is currently a hot-topic at the EPO ( IPKat ).

Invention 57

Invention Art Patent Licensing 57

Technology & Marketing Law Blog

JANUARY 2, 2023

Topics of conversation ranged from innocuous to serious, encompassing posts about parents discussing their own children, snow days and school closures, the school calendar, criticisms and concerns regarding District employees, and allegations that a District principal threatened a student. Atlas Biologicals, Inc.

Trademark 83

Trademark Social Media Registering Trademarks Intellectual Property 83

LexBlog IP

AUGUST 28, 2023

The ’124 application claimed an invention for maintaining “data structures representing categories of biological signals in a body such as a ‘Nervous System’ and a ‘Sensory System.’” This topic was recently previewed in Realtime Data v. In re Starrett , 2023 U.S.P.Q.2d ’” Id.

Invention 52

Invention Patent Application Art Patent 52

The IPKat

FEBRUARY 10, 2023

The topics covered were numerous and very technical (biologic drugs, second medical use patents, SPC waivers and divisional patents, just to name a few) and the synthesis abilities of this former Kat do not allow for them to be covered here.

Litigation 70

Litigation Reporting Patent Invention 70

Velocity of Content

SEPTEMBER 21, 2021

A few years later, in 1988, a paper by British researcher Andrew Wakefield, which claimed to find a correlative link between vaccines and autism, was published in a major biological journal. Later, Wakefield’s data was shown to have been falsified and his results utterly invalid.

Publishing 89

Publishing Journalism Editing Designs 89

IP and Legal Filings

FEBRUARY 26, 2023

iv] This division of responsibility and active allocation of funds from the state can act as another layer of checks when it comes to ensuring social security at the root level.

Government 83

Government Journalism Law IP 83

43(B)log

JULY 20, 2023

Certainly, Defendant Nepute made assertions about Vitamin D, zinc, COVID-19, and the vaccines, among other things, in his advertisements, but he often jumped from topic to topic and did not make connections between his statements. The court excluded the testimony of Dr. Parks, who had (as relevant) a Ph.D.

Government 52

Government Advertising Advertising Social Media 52

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 2, 2020

For more information about any topic herein, please see our October 20, 2020 webinar, “ IP and Cannabis: The Current Landscape ,” or contact your Fish attorney. Nevertheless, the current IP landscape surrounding cannabis, while very much in flux, does allow for some forms of IP protection and enforcement. FDA Regulation.

IP 52

IP Registration Trademark Branding 52

IP and Legal Filings

NOVEMBER 26, 2023

When the matter of conflict between two or more countries, or within a country is discussed, the topics that usually surrounds these discussions are the topics of economy, ammunition, advantages of a country, disadvantages of a country, biological and nuclear weapons etc.

Government 59

Government Reporting Law IP 59

SpicyIP

DECEMBER 24, 2023

In this month’s edition, he looks into topics including the Plant Variety Registry, different tales of/ takes on personality rights, and multiple leaks of key documents and their contribution in law-making. 6 of the Biological Diversity Act. vs The Controller of Patents & Anr. Novartis AG vs Novotas Pharmaceuticals Pvt.

Registration 52

Registration Trademark Copyright Registering Trademarks 52

IP and Legal Filings

MARCH 14, 2023

[iv] [Image Sources : Shutterstock] Even though traditional knowledge (TK) encompasses a wide range of subjects, nature-based knowledge is essential because it includes knowledge about safeguarding plants, having access to genetic resources, and managing biological resources sustainably. Both publicly and privately [v] , TK is practised.

Intellectual Property 52

Intellectual Property Journalism Ownership Higher Education 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

After a slow year in 2020 for biologics [1] at the PTAB, post-grant review of biologics was back on the rise in 2021. Following a year in which only three post-grant petitions were filed against patents covering biologic drugs, 2021 saw 18 biologic IPR petitions and 5 biologic PGR petitions filed. Back to Top.

Reporting 52

Reporting Art Invention Patent 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Litigation under the Biologics Price Competition and Innovation Act (BPCIA) in the district courts also decreased. Legislation and Executive Orders Relating to Biologics and Biosimilars. Yet, given fewer FDA approvals in 2020 and 2021, this year saw the lowest number of commercial launches since 2017. Biosimilar Regulatory Updates.

Litigation 52

Litigation Settlement Patent Marketing 52

SpicyIP

DECEMBER 30, 2023

As in previous years, we have divided these developments into five categories: a) Top 10 IP Judgements/Orders (Topicality/Impact) b) Top 10 IP Judgements/Orders (Jurisprudence/Legal Lucidity) c) Top 10 IP Legislative and Policy Related Developments d) Other IP Developments; and e) Other Notable Developments. RDB and Co.

IP 124

IP Copyright Trademark Intellectual Property 124

Patently-O

NOVEMBER 11, 2022

The scope afforded to chemical genus claims under 35 USC § 112(a)’s enablement and written description requirements has been hot topic recently (at least in certain quarters). Again, the gist of this example comes from an actual Federal Circuit decision, Noelle v.

Inventor 49

Inventor Invention Patent Reporting 49

SpicyIP

JANUARY 27, 2024

– Sifting through SpicyIP pages, I stumbled upon Madhulika Vishwanathan’s 2012 post critiquing the then-issued Guidelines enhancing standards of patentability for TK and Biological patents, which Prashant had previously examined against the backdrop of the revocation of the controversial Avesthagen.

IP 64

IP Licensing Copyright Blogging 64

Herbert Smith Freehills

MAY 31, 2022

Until then, we had no idea who was the 'biological' father (we didn’t feel like it was important during the pregnancy, but was required as part of the court papers). I had for some reason convinced that I was the biological father - I was wrong! I didn’t feel differently at all and I still don’t.

Music 52

Music Law Contracts Government 52

Herbert Smith Freehills

MAY 31, 2022

Until then, we had no idea who was the 'biological' father (we didn’t feel like it was important during the pregnancy, but was required as part of the court papers). I had for some reason convinced that I was the biological father - I was wrong! I didn’t feel differently at all and I still don’t.

Music 52

Music Law Business Contracts 52